MiMedx Group, Inc. Announces Regulatory Changes Impacting Coverage for Skin Substitute Grafts
Revised LCDs will eliminate coverage for over 200 unproven skin substitutes, promoting clinically validated treatments.Quiver AI SummaryMiMedx Group, Inc. announced that over 200 unproven skin substitute...
MiMedx Group (NASDAQ: MDXG) Reports Q1 2023 Financial Results Showing 21.7% Sales Growth
MiMedx Group, Inc. (NASDAQ: MDXG) is engaged as a biotechnology company that is focused as a placental biologics developer to
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END